Literature DB >> 10934165

Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease.

E B Mukaetova-Ladinska1, F Garcia-Siera, J Hurt, H J Gertz, J H Xuereb, R Hills, C Brayne, F A Huppert, E S Paykel, M McGee, R Jakes, W G Honer, C R Harrington, C M Wischik.   

Abstract

We have examined the relationships between dementia, loss of synaptic proteins, changes in the cytoskeleton, and deposition of beta-amyloid plaques in the neocortex in a clinicopathologically staged epidemiological cohort using a combination of biochemical and morphometric techniques. We report that loss of synaptic proteins is a late-stage phenomenon, occurring only at Braak stages 5 and 6, or at moderate to severe clinical grades of dementia. Loss of synaptic proteins was seen only after the emergence of the full spectrum of tau and beta-amyloid pathology in the neocortex at stage 4, but not in the presence of beta-amyloid plaques alone. Contrary to previous studies, we report increases in the levels of synaptophysin, syntaxin, and SNAP-25 at stage 3 and of alpha-synuclein and MAP2 at stage 4. Minimal and mild clinical grades of dementia were associated with either unchanged or elevated levels of synaptic proteins in the neocortex. Progressive aggregation of paired helical filament (PHF)-tau protein could be detected biochemically from stage 2 onwards, and this was earliest change relative to the normal aging background defined by Braak stage 1 that we were able to detect in the neocortex. These results are consistent with the possibility that failure of axonal transport associated with early aggregation of tau protein elicits a transient adaptive synaptic response to partial de-afferentation that may be mediated by trophic factors. This early abnormality in cytoskeletal function may contribute directly to the earliest clinically detectable stages of dementia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10934165      PMCID: PMC1850134          DOI: 10.1016/s0002-9440(10)64573-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  66 in total

1.  Cingulate cortex synaptic terminal proteins and neural cell adhesion molecule in schizophrenia.

Authors:  W G Honer; P Falkai; C Young; T Wang; J Xie; J Bonner; L Hu; G L Boulianne; Z Luo; W S Trimble
Journal:  Neuroscience       Date:  1997-05       Impact factor: 3.590

Review 2.  Tau proteins and neurofibrillary degeneration.

Authors:  M Goedert; M G Spillantini; R A Crowther
Journal:  Brain Pathol       Date:  1991-07       Impact factor: 6.508

Review 3.  Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives.

Authors:  M P Mattson
Journal:  Physiol Rev       Date:  1997-10       Impact factor: 37.312

4.  Synaptophysin immunoreactivity of the cortical neuropil in vascular dementia of Binswanger type compared with the dementia of Alzheimer type and nondemented controls.

Authors:  S S Zhan; K Beyreuther; H P Schmitt
Journal:  Dementia       Date:  1994 Mar-Apr

5.  Incidence of dementia and cognitive decline in over-75s in Cambridge: overview of cohort study.

Authors:  E S Paykel; F A Huppert; C Brayne
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1998-08       Impact factor: 4.328

6.  Identification of two distinct synucleins from human brain.

Authors:  R Jakes; M G Spillantini; M Goedert
Journal:  FEBS Lett       Date:  1994-05-23       Impact factor: 4.124

7.  Incidence of dementia in a population older than 75 years in the United Kingdom.

Authors:  E S Paykel; C Brayne; F A Huppert; C Gill; C Barkley; E Gehlhaar; L Beardsall; D M Girling; P Pollitt; D O'Connor
Journal:  Arch Gen Psychiatry       Date:  1994-04

8.  Fibroblast growth factor (FGF)-9 immunoreactivity in senile plaques.

Authors:  S Nakamura; K Arima; S Haga; T Aizawa; Y Motoi; M Otsuka; A Ueki; K Ikeda
Journal:  Brain Res       Date:  1998-12-14       Impact factor: 3.252

9.  Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease.

Authors:  C R Harrington; J Louwagie; R Rossau; E Vanmechelen; R H Perry; E K Perry; J H Xuereb; M Roth; C M Wischik
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

10.  Synaptic and neuritic alterations during the progression of Alzheimer's disease.

Authors:  E Masliah; M Mallory; L Hansen; R DeTeresa; M Alford; R Terry
Journal:  Neurosci Lett       Date:  1994-06-06       Impact factor: 3.046

View more
  72 in total

1.  Hsp70 ATPase Modulators as Therapeutics for Alzheimer's and other Neurodegenerative Diseases.

Authors:  Umesh K Jinwal; John Koren; John C O'Leary; Jeffrey R Jones; Jose F Abisambra; Chad A Dickey
Journal:  Mol Cell Pharmacol       Date:  2010-01-01

2.  Age-related decreases in SYN levels associated with increases in MAP-2, apoE, and GFAP levels in the rhesus macaque prefrontal cortex and hippocampus.

Authors:  Gwendolen E Haley; Steven G Kohama; Henryk F Urbanski; Jacob Raber
Journal:  Age (Dordr)       Date:  2010-04-13

3.  Insoluble alpha-synuclein in Alzheimer's disease without Lewy body formation.

Authors:  Melissa Broe; Claire E Shepherd; David M A Mann; Elizabeth A Milward; Wei-Ping Gai; Emma Thiel; Glenda M Halliday
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

4.  Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

Authors:  C Wischik; R Staff
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

5.  Apolipoprotein E*4 (APOE*4) Genotype Is Associated with Altered Levels of Glutamate Signaling Proteins and Synaptic Coexpression Networks in the Prefrontal Cortex in Mild to Moderate Alzheimer Disease.

Authors:  Robert A Sweet; Matthew L MacDonald; Caitlin M Kirkwood; Ying Ding; Tadhg Schempf; Jackie Jones-Laughner; Julia Kofler; Milos D Ikonomovic; Oscar L Lopez; Megan E Garver; Nicholas F Fitz; Radosveta Koldamova; Nathan A Yates
Journal:  Mol Cell Proteomics       Date:  2016-04-21       Impact factor: 5.911

6.  Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease.

Authors:  A Parachikova; C W Cotman
Journal:  Neurobiol Dis       Date:  2007-07-10       Impact factor: 5.996

7.  Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease.

Authors:  Natalia Louneva; Julia W Cohen; Li-Ying Han; Konrad Talbot; Robert S Wilson; David A Bennett; John Q Trojanowski; Steven E Arnold
Journal:  Am J Pathol       Date:  2008-09-25       Impact factor: 4.307

8.  Folic acid prevents habituation memory impairment and oxidative stress in an aging model induced by D-galactose.

Authors:  Michelle Lima Garcez; Ricardo Chiengo Sapalo Cassoma; Francielle Mina; Tatiani Bellettini-Santos; Aline Pereira da Luz; Gustavo Luis Schiavo; Eduarda Behenck Medeiros; Ana Carolina Brunatto Falchetti Campos; Sabrina da Silva; Lisienny Campoli Tono Rempel; Amanda Valnier Steckert; Tatiana Barichello; Josiane Budni
Journal:  Metab Brain Dis       Date:  2020-11-21       Impact factor: 3.584

9.  Cerebrospinal fluid biomarkers for dementia with lewy bodies.

Authors:  Elizabeta B Mukaetova-Ladinska; Rachael Monteith; Elaine K Perry
Journal:  Int J Alzheimers Dis       Date:  2010-10-17

Review 10.  The role of microglia in synaptic stripping and synaptic degeneration: a revised perspective.

Authors:  V Hugh Perry; Vincent O'Connor
Journal:  ASN Neuro       Date:  2010-10-14       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.